Latest Breaking News On - Human drug research - Page 1 : comparemela.com

Immutep s anti-cancer clinical trials advancing rapidly – here are next catalysts for investors

Immutep s anti-cancer clinical trials advancing rapidly – here are next catalysts for investors
theaustralian.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaustralian.com.au Daily Mail and Mail on Sunday newspapers.

United statesMarc voigtByeddy sunartoMerck coCentre for human drug researchEuropean medicines agencyAmerican society of clinical oncologyFrankfurt institute of clinical cancer researchAmerican societyClinical oncologyEftilagimod alphaFrankfurt instituteClinical cancer researchHuman drug research

Hot Money Monday: Expert says buying stock at 52-week high is better than buy low - sell high strategy

Hot Money Monday: Expert says buying stock at 52-week high is better than buy low - sell high strategy
stockhead.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stockhead.com.au Daily Mail and Mail on Sunday newspapers.

Nifty copper mineWestern australiaSaudi arabiaPuerto las losasMark minerviniAdmiralty minerals chileCentre for human drug researchMacmahon holdingsEnergy fuelsMayfield groupDecmil groupBisalloy steel groupAxiom propertiesVinyl groupGalilee energySaudi ministry of investment

Algernon NeuroScience and the Centre for Human Drug

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT:.

Noord hollandUnited kingdomBritish columbiaChristopherj moreauRick strassmanAlgernon pharmaceuticals incConstraint induced movement therapyAlgernon pharmaceuticalsCentre for human drug researchSeyltx incInterdisciplinary conference on psychedelic researchCompany phaseAlgernon neuroscienceHuman drug researchInterdisciplinary conferencePsychedelic research

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New south walesMatthijs moerlandChris bastaPediatric researchImmutep limitedCentre for human drug researchCorporate communicationsAppoints leading research instituteConduct first in human phasei studyHuman drug researchChief scientific officerDirector immunologyPrincipal investigatorLymphocyte activationInvestor relationsCurr opin

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD $2M cash and a 20% common share

British columbiaUnited kingdomChristopherj moreauCompany or algernonAlgernon pharmaceuticalsAlgernon pharmaceuticals incCentre for human drug researchCompany phaseAlgernon neuroscienceStroke studyHuman drug researchAlgernon pharmaceuticals incClinical trial designResearch programAlgernon neuroscience